Jazz Pharmaceuticals

Jazz Pharmaceuticals

Pharmaceutical Manufacturing

About us

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Website
http://www.jazzpharma.com
Industry
Pharmaceutical Manufacturing
Company size
1,001-5,000 employees
Headquarters
Dublin
Type
Public Company
Founded
2003
Specialties
Biopharmaceutical , innovation, research and development , great place to work, neuroscience , epilepsy, sleep disorders, oncology, and hematology

Locations

Employees at Jazz Pharmaceuticals

Updates

  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    We’re pleased to announce that Samantha Pearce, Senior Vice President, Europe and International, has been promoted to Chief Commercial Officer effective August 1, 2024. With over 30 years of commercial experience in the pharmaceutical industry, Sam is an inspiring leader who will help us to drive continued transformational growth for our global commercial business in support of our mission to deliver pioneering medicines for people living with serious diseases.

    • No alternative text description for this image
  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    Our 2023 Corporate Sustainability and Social Impact (CSSI) Report is now live here: https://bit.ly/3zmqaqZ    Our values anchor our corporate strategy and support our commitment to generating positive outcomes for patients, employees and other stakeholders. In 2023, we emphasized strengthening the governance of our CSSI strategy to ensure we can deliver positive impact across our key pillars.    We will continue to strive for sustainable growth and enhanced value while focusing on reducing our environmental footprint and furthering our capabilities as a responsible and innovative biopharmaceutical company.

  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    We’re at the 2024 ESMO - European Society for Medical Oncology Gastrointestinal Cancers Congress to present our latest data and contribute to greater understanding of difficult-to-treat #GastrointestinalCancers, such as biliary tract cancer (BTC). Although BTC accounts for less than 1% of all adult cancers, an estimated 35,000 people are diagnosed in Europe every year. Hear from our VP of Medical Affairs Europe & International, Tomas Skacel, on the need for greater awareness and early recognition of BTC, and for healthcare professionals onsite at #ESMOGI24 this week, visit us at booth #31.

  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    Today, on International #DravetAwarenessDay, we are supporting charities, families and organizations around the world in raising awareness of #DravetSyndrome (DS). DS is a rare, severe and lifelong form of epilepsy that usually begins in the first year of life and leads to some level of developmental disability and dependency on caregivers. Isabella Brambilla, Chairperson of Dravet Italia Onlus, discusses the broader impact of DS on family life, drawing on her own experience caring for her son, who lives with the condition. Your local Dravet Syndrome foundation, such as Dravet Italia Onlus, is a great place to go to access resources for those living with DS, or visit the Dravet Syndrome Foundation.

  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    Something new is on the horizon! Our careers website and jobs feed are undergoing renovations until June 26th and will be temporarily unavailable.      We appreciate your patience during this time. Please check back after June 26th to explore our updated careers experience and discover exciting job opportunities! If you would like to be notified when the site is live, please email talentacquisitionprograms@jazzpharma.com

    • No alternative text description for this image
  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    In celebration of #Juneteenth, we welcomed Dr. Damon Tweedy, M.D., renowned professor of psychiatry and behavioral sciences at Duke University Medical Center and staff physician at the Durham VA Medical Center, to share his personal experiences and insights on healthcare inequities in the U.S.     Dr. Tweedy has written extensively about the intersection of race, medicine and mental health and we are honored to have had this opportunity to learn firsthand from him to commemorate this holiday.

    • No alternative text description for this image
  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    At the 2024 #ASAPAwards, we were thrilled to be selected as the winner for both the Innovative Best Alliance Practice and Individual Alliance Excellence, Emerging categories. In celebration of this honor, members of our Alliance Management team shared how we are continuing to advance our alliance practices to be a partner of choice and deliver for the business.     We are extremely grateful for this recognition by the Association of Strategic Alliance Professionals and look forward to furthering our commitment to the value and investment in strategic alliance management. 

    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    In celebration of #PrideMonth, we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for understanding and allyship by shedding light on her lived experiences and the challenges she’s faced as a trans woman living in India and the U.S. We believe in creating a welcoming and inclusive society for all members of the LGBTQ+ community, and we appreciate Celia's courage in sharing her personal journey and highlighting the importance of transformative allyship.

    • No alternative text description for this image
  • View organization page for Jazz Pharmaceuticals, graphic

    162,284 followers

    Our people are what make Jazz a great place to work, and we are inspired by team members like Myra Beaudoin Bertrand, MBA, PhD.   Myra recently went on an expedition to Mount Everest and successfully summited the world’s tallest peak from Tibet while proudly displaying the Jazz flag. We are so proud of Myra for this incredible achievement and constant pursuit of excellence.   We celebrate our team members' passions both inside and outside of the workplace and are grateful Myra chose to make Jazz a part of her remarkable journey to the top of the world! 

Similar pages

Funding

Jazz Pharmaceuticals 6 total rounds

Last Round

Post IPO debt

US$ 1.5B

See more info on crunchbase